Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates

Cel

Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP

Dziedzina nauki

Słowa kluczowe

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

H2020-PHC-2014-2015

Zobacz inne projekty w ramach tego zaproszenia

Szczegółowe działanie

H2020-PHC-2015-single-stage_RTD

System finansowania

RIA - Research and Innovation action

Koordynator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Wkład UE netto
€ 1 895 923,68
Adres
RUE DE TOLBIAC 101
75654 Paris
Francja

Zobacz na mapie
Region
Ile-de-France Ile-de-France Paris
Rodzaj działalności
Research Organisations
Linki
Koszt całkowity
€ 2 118 826,93

Uczestnicy (46)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 11 Listopada 2024

Moja broszura

Permalink: https://cordis.europa.eu/project/id/681032/pl

European Union, 2024